Daily Job Search Advice | Career Advancement Tips | Informative Articles on Life Lessons And much more...
Tauriga Sciences, that develops proprietary technology platform in the nano-robotics space, has announced on January 6th that it has received a positive update from Immunovative Therapies Limited (ITL). Tauriga also gets its revenue from license agreements. On January 2nd 2014, ITL had informed Tauriga Sciences that it would restarting its clinical trials in Thailand, for metastatic cancer, and in Israel, for liver cancer, sometime later this month. ITL has also come out with pills store a new website that focuses on educating patients about the upcoming Allovax trials.
ITL has also announced plans for Get the best Rumalaya liniment deals at our online store today! Take a look at our offers and buy your Rumalaya liniment for only 46 USD! launching phase II and III trial for breast cancer in the month of April 2014. Tauriga’s CEO Seth M. Shaw has remarked that his company is extremely happy on hearing the trial plans announced by ITL, particularly with respect to breast cancer phase II and Phase III trials. Tauriga has invested a significant amount of equity investment into ITL and is hopeful of a positive outcome from these planned trials. Tauriga Sciences Inc. had invested $3,700,000 into ITL and purchased 3,280,000 shares of ITL. This equity investment is in line with the main objective of Tauriga, which buy cheat drugs on line – http://globalgold.wpengine.com/?p=1847 is to provide significant value to shareholders.
For more details on the article Click Here